
According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

Despite its status as an essential postoperative safety eye product and its utilization by every ocular surgeon with every ocular surgery, eye shield innovation has been neglected to date.

Earlier this year, the US Centers for Disease Control and Prevention issued an advisory, sounding the alarm for an outbreak of a drug resistant strain of the bacteria Pseudomonas aeruginosa that was connected to the use of artificial tears.

The company has released a video presentation that highlights combining genetic markers with high-resolution retinal imaging to assist in the detection and treatment of blindness and multiple systemic diseases.

Noncontact esthesiometry screens for all levels of neurotrophic keratitis.

The glaucoma specialist spoke about his ESCRS agenda–and his calendar for 2024

Stem cells may replace some lost retinal neurons

The week of September 18-24 will be dedicated to educating the public on IEDs such as uveitis, keratitis, conjunctivitis and more.

With a robust pipeline, new hope for Stargardt disease and retinitis pigmentosa may be on the horizon.

Clear communication, transparent priceing, options are key to positive experience

The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration

Garg reported the 30-month data showing that patients receiving pegcetacoplan experienced an increasing treatment effect compared with sham (ie, a decrease in GA lesion area over time).

A panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?

Research from Orbis International analyzes the overall wellbeing of children with common childhood vision problems.

According to a study, optical coherence tomography-based elastography holds promise for research and diagnosis of ocular diseases.

In recent panel discussions, leaders in the retina space shared their thoughts around AMD and DME. These key quotes showcase the heart of these discussions.

The AI retinal scanning model will be free to use for all institutions.

A panel of retina experts discussed the challenges presented in the management of DME. Which do you think is the biggest of these challenges?

The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.

A Knox County Circuit Court jury awarded Gerald McCoy $6 million and his wife Deborah McCoy should $1 million after March 2017 procedure resulted in the loss of his eye.

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.


A panel of retina specialists weighed in on the dosing intervals when using of faricimab for the treatment of neovascular AMD in the clinical practice setting. Do you agree with them?

The competition is offering an opportunity for amateur and professional photographers to demonstrate their skills and share with the world what they see and what it means to #LoveYourEyes.

According to the Louisiana State University Health Sciences Center, elovanoids have been shown to restore the structure and integrity of damaged photoreceptor cells by repairing, remodeling and regenerating healthy cells.

New cataract and refractive options from STAAR Surgical could come as early as this year

A panel of esteemed retina specialists recently delved into innovative therapies for neovascular age-related macular degeneration and diabetic macular edema, focusing on personalized treatment, telemedicine, and the ongoing quest for advancements.

The AI retinal scanning model will be free to use for all institutions

Two members of the team gave a preview of Geuder’s 2024 spotlight products